Irma Olarte-Carrillo, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Christian O. Ramos-Peñafiel, Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
Rafael Cerón-Maldonado, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Gilberto I. Barranco-Lampon, Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
Iveth Mendoza-Salas, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Anel I. García-Laguna, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Adrian De la Cruz-Rosas, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Carlos Martínez-Murillo, Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico
Federico Centeno-Cruz, Immunogenic and Metabolic Diseases Laboratory, Instituto Nacional De Medicina Genómica (INMEGEN). Mexico City, Mexico
Adolfo Martínez-Tovar, Molecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, Mexico


Objective: Our objective was to evaluate the frequency of expression and determine the expression levels of the NY-ESO-1 gene in patients with DLBCL as well as to examine its relationship with clinical parameters and survival. Methods: We analyzed NY-ESO-1 gene expression levels using real-time quantitative RT-PCR (RT-qPCR) in 112 patients with DLBCL. The associations between the expression of the NY-ESO-1 gene and the clinical variables were evaluated using the Chi-square test and Fisher’s exact test. Overall survival (OS) was determined using the Kaplan–Meier method. Result: The results showed that the NY-ESO-1 gene was expressed in 46.4% (52/112) of patients with DLBCL, and NY-ESO-1 gene expression was associated with clinical parameters such as LDH, clinical stage, and International Prognostic Index (IPI) (p ≤ 0.05). High levels of NY-ESO-1 gene expression were associated with advanced disease stages, and the survival rates after 5.3 years of tracking were lower in the patients expressing the NY-ESO-1 gene (66.4%) than in those not expressing the gene (23.1%). Conclusion: The expression levels of the NY-ESO-1 gene in patients with DLBCL may be of great utility for diagnosing and determining the prognosis of this disease.



Keywords: DLBCL. NY-ESO-1. Lymphoma.